Aprepitant CAS 170729-80-3 API Active Pharmaceutical Ingredient

Product Description:

Product Name: Aprepitant CAS NO: 170729-80-3

Synonyms:

5-[{(2R,3S)-2-((1R)-1-3,5-bis(trifluoro-methyl)phenylethoxy)-3-(4-fluorophenyl)-4-morpholinyl}methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one;

Aprepitant (MK-0869, L-754030);

MK-0869;

Chemical & Physical Properties:

Appearance: Off-white to light yellow crystalline solid

Assay :≥99.00%

Density: 1.51 g/cm3

Melting Point: 75-76℃(lit.)

Refractive Index: 1.564

Storage Condition: -20℃ Freezer

Safety Information:

Safety Statements: S26; S36

WGK Germany: 3

Risk Statements: R20/21/22; R36/37/38

Hazard Codes: Xn; Xi

HS Code: 2934990002

Symbol: GHS07

Signal Word: Warning

Hazard Statement: H319

Precautionary Statements: P305 + P351 + P338

Aprepitant (brand name: Emend (the brand name used in all English-speaking countries)) is an antiemetic chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by blocking the neurokinin 1 (NK1) receptor.

Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003.

Aprepitant may also be useful in the treatment of cyclic vomiting syndrome & late-stage chemotherapy induced vomiting, but there are few studies to date.

On January 2008, the FDA approved fosaprepitant, an intravenous form of aprepitant, which is to be sold under the tradename Emend Injection in the US and as Ivemend in some other countries.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.